Role of intrathecal chemotherapy in the management of meningeal carcinomatosis in patients with breast cancer

Abstract

This retrospective cohort study included 109 patients. Statistical analyses were performed for the treatment Groups Intrathecal Chemotherapy versus No Intrathecal Chemotherapy and adjusted for potential confounders. The authors demonstrated that intrathecal chemotherapy did not increase the overall survival or time to neurological deterioration in patients with leptomeningeal metastatic breast cancer. The median survival time was less than 3 months in both groups.